Prognostic factors for atherosclerosis progression in saphenous vein grafts The postcoronary artery bypass graft (post-CABG) trial by Domanski, Michael J. et al.
Prognostic Factors for Atherosclerosis
Progression in Saphenous Vein Grafts
The Postcoronary Artery Bypass Graft (Post-CABG) Trial
Michael J. Domanski, MD, FACC,* Craig B. Borkowf, PHD,† Lucien Campeau, MD, FACC,‡
Genell L. Knatterud, PHD,§ Carl White, MD, FACC,\ Byron Hoogwerf, MD,¶
Yves Rosenberg, MD, MPH,* Nancy L. Geller, PHD,† and the Post-CABG Trial Investigators#
Bethesda and Baltimore, Maryland; Minneapolis, Minnesota; Cleveland, Ohio; and Montreal, Canada
OBJECTIVES The study was done to assess patients in the Post-Coronary Artery Bypass Graft (Post-
CABG) trial to determine prognostic factors for atherosclerosis progression.
BACKGROUND Saphenous vein grafts (SVGs) are effective in relieving angina and, in certain patient subsets,
in prolonging life. However, the progression of atherosclerosis in many of these grafts limits
their usefulness.
METHODS The Post-CABG trial studied moderate versus aggressive lipid-lowering and low-dose
warfarin versus placebo in patients with a history of coronary artery bypass surgery and found
that more aggressive lipid lowering was effective in preventing progression of atherosclerosis
in SVGs, but warfarin had no effect. Using variables measured at baseline, we sought the
independent prognostic factors for atherosclerosis progression in SVGs, employing the
statistical method of generalized estimating equations with a logit-link function.
RESULTS Twelve independent prognostic factors for atherosclerosis progression were found. In the
order of their importance they were: maximum stenosis of the graft at baseline angiography;
years post-SVG placement; the moderate low-density lipoprotein–cholesterol (LDL-C)
lowering strategy; prior myocardial infarction; high triglyceride level; small minimum graft
diameter; low high-density lipoprotein–cholesterol (HDL-C); high LDL-C; high mean
arterial pressure; low ejection fraction; male gender; and current smoking.
CONCLUSIONS This study identified Post-CABG patient and SVG characteristics associated with saphenous
vein graft atherosclerosis progression. These data provide a basis for rational risk factor
management to prevent progression of SVG atherosclerosis. (J Am Coll Cardiol 2000;36:
1877–83) © 2000 by the American College of Cardiology
Aortocoronary saphenous vein bypass grafts (SVGs) are
effective in the relief of angina and, in certain patient
subsets, in prolonging life (1,2). However, the development
and progression of atherosclerosis limits the duration of
SVG usefulness. About 15% of SVGs are closed within 1
year (3–5). Between one and six years, the annual graft
attrition rate is 1% to 2% and becomes 4% to 6% per year
after that, so that about half of SVGs have significant
stenosis or are occluded after 10 years. The development of
vein graft atherosclerosis results in recurrent angina and the
acute coronary syndromes. By 10 years, nearly one-third of
patients undergo percutaneous or operative intervention (6).
Second procedures carry more risk and are less likely to be
successful than the initial operation (7).
Most of the stenosis and occlusion after the first year is
caused by atherosclerosis. Prior studies have suggested that a
number of prognostic factors for atherosclerosis progression in
native arteries are operative in SVGs, including hyperlipidemia
(7). The recently completed Post-Coronary Artery Bypass
Graft (Post-CABG) trial demonstrated that aggressive, rather
than moderate, treatment to lower serum cholesterol reduced
significant progression of atherosclerosis in SVGs, whereas
low-dose (1 to 4 mg daily) warfarin had no effect (8).
Attempts to improve treatment to prevent progression of
SVG atherosclerosis would benefit from an improved un-
derstanding of definable prognostic factors and their relative
order of importance. To this end, we studied the well-
characterized patients entered into the Post-CABG trial (8)
to determine prognostic factors associated with progression
of atherosclerosis in SVGs and determined the relative
contribution of these prognostic factors.
METHODS
Post-CABG trial study design. The design of Post-
CABG has been described previously (8). Briefly, patients 1
to 11 years’ postcoronary bypass surgery who met eligibility
criteria were randomized in a 2 3 2 factorial design to
moderate lipid lowering or more aggressive lipid lowering
with lovastatin and, when necessary, to cholestyramine as
well as to low-dose warfarin or placebo at baseline angiog-
raphy. Each SVG was divided into three segments. Percent
stenosis was determined as (1 2 minimum graft diameter)/
(maximum graft diameter in the corresponding graft seg-
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ment) 3 100. This means that the minimum graft diameter
was not constrained to occur at the site of maximum
stenosis. The baseline angiogram had at least two patent
SVGs with stenosis ,75% in men and at least one patent
SVG in women; all patients had ejection fraction $0.30. All
subjects were aged 21 to 74 years, and all had low-density
lipoprotein cholesterol (LDL-C) levels 130 to 175 mg/dl
and triglyceride levels below 300 mg/dl. In all, 1,351
patients were entered into the study; 92% were men and
94% white. The mean age was 61.5 years.
Follow-up angiograms were performed four to five years
after enrollment to assess atherosclerotic progression. The
primary end point of the study was the per-patient percent-
age of initially patent major grafts that had graft progression
of atherosclerosis (“graft worsening”—that is, a decrease of
$0.6 mm in lumen diameter) at the site of greatest change
at follow-up.
The goal of this secondary analysis of the Post-CABG
data was to determine prognostic factors for graft worsen-
ing.
Statistical analysis. Baseline measurements of potential
prognostic value for significant graft worsening were se-
lected by the investigators and are listed in Tables 1 and 2.
Continuous baseline measurements were compared in the
two LDL-C lowering strategies using Satterthwaite’s test
for the equality of means without equal variances (9).
Dichotomous baseline variables (yes or no, or presence or
absence of a characteristic) were compared using the Fisher
exact test for the equality of proportions (10).
A logit-link function (10) was chosen to relate the
dichotomous response variable of significant graft worsen-
ing to the potential prognostic (predictor) baseline variables
listed in Tables 1 and 2. Let p denote the probability of
significant worsening of a graft. The logit-link function
models the natural log odds of p, g(p) 5 loge(p/[1 2 p]), as
a linear combination of an intercept (b0), selected variables
(xi), and their corresponding parameter coefficients (bi), i.e.,
g~p! 5 b0 1 b1x1 1 b2x2 1 . . . 1 bnxn. [1]
Hence, the probability of graft progression can be written
directly as
p 5 $1 1 exp @b0 1 b1x1 1 b2x2 1 . . . 1 bnxn#21%21. [2]
The b-coefficients were estimated from the data set using
generalized estimating equations (GEE) (11), using a Statis-
tical Analysis System (SAS) module written by Dr. Margaret
M. Frederick (Clinical Trials & Surveys Corp.). This module
obtains initial parameter estimates for a given model using the
generalized linear model (GLM) and then iteratively solves the
GEE equations to obtain the final GEE estimates. The GEE
method takes into account the correlation among grafts within
Abbreviations and Acronyms
CHD 5 coronary heart disease
GEE 5 generalized estimating equation
GLM 5 generalized linear model
HDL-C 5 high-density lipoprotein cholesterol
LDL-C 5 low-density lipoprotein cholesterol
Post-CABG 5 Post-Coronary Artery Bypass Graft trial
SAS 5 Statistical Analysis System
SVG 5 saphenous vein graft
Table 1. Summary of Continuous/Ordinal Baseline Measurements by Lipid-Lowering
Treatment Assignment*
LDL-C
Lowering
(Moderate
Regimen)
LDL-C
Lowering
(Aggressive
Regimen)
Test of
Equal Means
Mean 6 SD Mean 6 SD p Value
Age (yrs) 61.4 6 7.4 61.7 6 7.3 0.39
Years since CABG operation 4.9 6 2.6 4.9 6 2.5 0.76
Minimum diameter of graft (mm) 2.8 6 0.6 2.9 6 0.6 0.48
Maximum stenosis of graft (%) 13.3 6 14.1 12.3 6 13.8 0.20
Total cholesterol (mg/dl) 227.6 6 26.0 226.0 6 25.2 0.30
HDL cholesterol (mg/dl) 39.4 6 10.1 39.1 6 9.3 0.64
LDL cholesterol (mg/dl) 155.6 6 20.1 155.4 6 20.4 0.82
Triglycerides (mg/dl) 161.8 6 73.1 158 6 66 0.33
Number of grafts 3.2 6 1.0 3.2 6 1.0 0.78
Ejection fraction 57.0 6 12.0 56.4 6 12.0 0.30
Body mass index 27.5 6 4.4 28.0 6 4.6 0.083
Systolic blood pressure (mm Hg) 133.9 6 17.4 134.9 6 17.8 0.37
Diastolic blood pressure (mm Hg) 80.2 6 9.0 79.4 6 9.0 0.13
Pulse pressure (mm Hg) 53.7 6 14.3 55.3 6 14.8 0.044
Mean arterial pressure (mm Hg) 98.1 6 10.5 97.9 6 10.5 0.72
*The sample sizes for the moderate and aggressive LDL-C lowering strategy treatment levels were 675 and 676, respectively,
except the following: number of grafts (moderate 5 675, aggressive 5 675); minimum diameter of graft (moderate 5 572,
aggressive 5 585); maximum stenosis of graft (moderate 5 623, aggressive 5 623); ejection fraction (moderate 5 672,
aggressive 5 671). The averages for the angiographic variables were obtained by averaging over grafts within each subject and
then averaging between subjects.
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a subject and allows for each subject to have a different number
of grafts. An unstructured correlation matrix was chosen,
although the GEE method is robust to correlation matrix
misspecification. All computations were performed in the SAS
6.12 programming language.
Because software for automated stepwise GEE proce-
dures was not available, a modified version of backward
elimination was used to select the best model. First, all
variables were entered into the model, and those with p
values greater than a threshold of 0.75 were eliminated. This
step was repeated with thresholds of 0.5, 0.4, 0.3, 0.1, and
0.05. In a modified version of a forward step, variables with
p values between 0.05 and 0.3 were individually added to a
model that included all variables previously significant at the
5% level to see whether the newly added variable contrib-
uted further.
Highly correlated or colinear variables were not included
in the same model. For example, separate models were
constructed with (a) total cholesterol and (b) the three
cholesterol components: high-density lipoprotein (HDL),
LDL, and triglycerides, and then the model with better
overall properties was chosen. Also, because a number of
patients were missing some angiographic measurements,
separate GEE models were constructed with and without
the angiographic variables.
Because there do not exist well-established goodness-
of-fit tests for GEE models (12), the goodness-of-fit
statistics from the GLM (e.g., deviance, G2) were used as a
surrogate. This choice was justified by the fact that the GEE
and GLM methods give close point estimates and estimated
variances.
To determine the relative significance of the variables
included in the final model, a forward selection method was
used to reconstruct the final model, with changes in the
deviance (G2) used to assess improvement in fit of the
model as variables were added. Each of the subsequent
reductions in deviance (DG2) has approximately a chi-
square distribution with 1 degree of freedom. This deter-
mined an ordering of the final prognostic variables from
most to least important, as assessed by deviance.
RESULTS
Tables 1 and 2 show the variables that were considered as
potential prognostic factors in these analyses. Baseline lipid
levels and blood pressures were those most recently obtained
prior to enrollment. Patient self-report determined use of
current medications. A question on antithrombotic use was
added after the first 84 patients were enrolled, and thus
information was incomplete on this variable.
Table 1 shows the means and standard deviation (SD) for
the selected continuous variables at baseline for the two
lipid-lowering treatment groups. These variables had ap-
proximately the same means in the two strategies, with two
exceptions. The baseline mean body mass index (BMI) for
the moderate group was lower than that of the aggressive
group (p 5 0.083) and the mean baseline pulse pressure was
significantly lower in the moderate group (p 5 0.044).
Nevertheless, there was substantial overlap between the
Table 2. Summary of Dichotomous Baseline Measurements by Lipid-Lowering
Treatment Assignment*
LDL-C
Lowering
(Moderate
Regimen)
LDL-C
Lowering
(Aggressive
Regimen)
Test of
Equal
Proportions
n (% 6 SD%) n (% 6 SD%) p Value
Warfarin treatment 337 (50 6 50) 337 (50 6 50) 1.00
Women 46 (07 6 25) 56 (08 6 28) 0.35
Nonwhite 38 (06 6 23) 38 (06 6 23) 1.00
Any aspirin (pill, drug) use 503 (75 6 44) 529 (78 6 41) 0.11
Antithrombotics use 27 (04 6 20) 34 (05 6 22) 0.43
Beta-blocker use 161 (24 6 43) 172 (25 6 44) 0.53
Calcium channel blocker use 138 (20 6 40) 181 (27 6 44) 0.007
Oral anti-diabetic use 37 (05 6 23) 52 (08 6 27) 0.12
Insulin use 16 (02 6 15) 11 (02 6 13) 0.34
Any anti-diabetic drug use 53 (08 6 27) 63 (09 6 29) 0.38
Thiazide diuretic use 71 (11 6 31) 72 (11 6 31) 1.00
Alcohol $1 times per week 310 (46 6 50) 284 (42 6 49) 0.15
Family history of CHD 476 (71 6 46) 474 (70 6 46) 0.95
Prior MI 328 (49 6 50) 334 (49 6 50) 0.79
Prior stroke 19 (03 6 17) 18 (03 6 16) 0.87
Hypertension 206 (31 6 46) 212 (31 6 46) 0.77
Never smoked 177 (26 6 44) 165 (24 6 43) 0.45
Quit smoking .2 years ago 392 (58 6 49) 390 (58 6 49) 0.91
Quit smoking ,2 years ago 35 (05 6 22) 43 (06 6 24) 0.41
Current smoker 71 (11 6 31) 78 (12 6 32) 0.60
*Sample sizes: moderate 5 675, aggressive 5 676.
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sample distributions of these variables, so they were not
considered unbalanced.
Table 2 shows the numbers of observations and the
proportions for “yes” outcomes of the selected dichotomous
variables at baseline for the two lipid-lowering treatment
groups. There was balance for these variables, except that
the proportion of patients in the aggressive group using
calcium channel blockers was greater than in the moderate
group (20% for the moderate group vs. 27% for the
aggressive group, p 5 0.007).
Thus, it appears that the moderate treatment group
might have had a small advantage in baseline factors over
the aggressive treatment group. No warfarin versus placebo
comparisons were considered because no warfarin effect was
found in the Post-CABG trial (8).
Of the 1,351 patients enrolled in the Post-CABG trial, one
was not eligible because there was at least 75% stenosis in all
grafts, and 94 patients had missing outcome variables. Of the
remaining 1,256 patients, some had missing baseline patient or
subject–graft data: 8 patients had missing ejection fractions,
including one who also had no subject–graft measurements for
minimum diameter but had complete subject–graft measure-
ments for maximum stenosis, leaving 1,248 patients. Of these,
1,105 patients had complete angiographic measurements; 98
additional patients had no subject-graft measurements for
minimum diameter, of whom 10 had no, 19 had some (but not
all), and 69 had all subject-graft measurements for maximum
stenosis; and 45 patients had some subject-graft measurements
for minimum diameter, of whom 25 had some and 20 had
complete subject-graft measurements for maximum stenosis.
These missing data reduced the total number of subject-graft
measurements to 2,663 (in 1,248 patients) and 2,422 (in 1105
patients) without and with the inclusion of the angiographic
variables, respectively. For the GEE analysis, missing measure-
ments were regarded as occurring at random, and thus patients
with missing responses or ejection fractions and subject–grafts
with missing angiographic measurements were deleted. In
addition, one patient had a missing history of coronary heart
disease (CHD), and 84 patients had missing antithrombotic
drug use because this variable was added after the study began.
Separate analyses were performed with and without these
variables, which did not enter the final model.
Table 3 shows the 12 predictors in the final GEE model.
For each predictor variable, the parameter estimates, esti-
mated standard errors, p values, and odds ratios (ORs) with
95% confidence intervals (CIs) are shown. The predictor
variables are listed in the order that they entered the GLM.
Thus, all of these variables contributed a significant reduc-
tion in deviance over the variables that preceded them in the
GLM estimation. The p value for the reduction in deviance
is also shown. Thus, corresponding to equation (2), the
estimated equation for the probability of significant graft
worsening as a function of these prognostic variables is:
P ~significant graft worsening! 5 $1 1 exp @24.5756
1 0.0481 ~maximum stenosis of graft!
1 0.1637 ~years since CABG operation!
2 0.5951 ~1 if aggressive LDL-C strategy!
1 0.3862 ~1 if prior MI! 1 0.0027 ~triglycerides!
1 0.1896 ~minimum diameter of graft!
2 0.0170 ~HDL-C! 1 0.0094 ~LDL-C!
1 0.0126 ~mean arterial pressure!
2 0.0108 ~ejection fraction! 2 0.5733 ~1 if female!
1 0.3839 ~1 if current smoker!#21%21. [3]
A positive coefficient indicates a direct relationship with
graft worsening. Thus, the independent prognostic factors
that make graft worsening more likely (in order of decreas-
ing reduction in deviance) are: greater maximum stenosis of
a graft; more years post-CABG; assignment to moderate
Table 3. Estimates of Parameters, Standard Errors, and Odds Ratios for GEE Model for Graft Worsening as a Function of
Baseline Variables
Parameter Odds Ratio
Reduction in Deviance
(DG2)
Estimate SE p Value Estimate 95% CI Deviance p Value
Intercept 24.5756 0.7901 , 0.0001
Maximum stenosis of graft (%) 0.0481 0.0033 , 0.0001 1.05 (1.04, 1.06) 307.1 0.0001
Years since CABG operation 0.1637 0.0216 , 0.0001 1.18 (1.13, 1.23) 74.3 0.0001
LDL-C lowering treatment (aggressive) 20.5951 0.1103 , 0.0001 0.55 (0.44, 0.68) 38.1 0.0001
Prior MI* 0.3862 0.1162 0.0009 1.47 (1.17, 1.85) 27.2 0.0001
Triglycerides (mg/dl) 0.0027 0.0008 0.0013 1.00** (1.00, 1.00)** 25.7 0.0001
Minimum diameter of graft (mm) 0.1896 0.0714 0.0079 1.21 (1.05, 1.39) 13.7 0.0002
HDL cholesterol (mg/dl) 20.0170 0.0065 0.0085 0.98 (0.97, 1.00) 9.8 0.0017
LDL cholesterol (mg/dl) 0.0094 0.0028 0.0007 1.01 (1.00, 1.02) 12.5 0.0004
Mean arterial pressure (mm Hg) 0.0126 0.0055 0.0208 1.01 (1.00, 1.02) 6.1 0.0139
Ejection fraction 20.0108 0.0049 0.0269 0.99 (0.98, 1.00) 5.9 0.0147
Women* 20.5733 0.2761 0.0379 0.56 (0.33, 0.97) 4.3 0.0371
Current smoker* 0.3839 0.1775 0.0306 1.47 (1.04, 2.08) 4.3 0.0388
*1 5 yes, 0 5 no. **Accurate to three decimal places.
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(rather than aggressive) LDL-C lowering; prior myocardial
infarction (MI); high triglycerides; smaller minimum diam-
eter of the graft; low HDL-C; high LDL-C; high mean
arterial pressure; low ejection fraction; being male rather
than female; and being a current smoker.
Let b denote an estimated b-coefficient and X denote a
predictor variable. Then exp (Xb) gives the OR for the
corresponding predictor variable when all other predictor
variables are fixed. For a dichotomous variables, exp (b)
indicates how much greater the odds of significant graft
worsening are for a subject with a “yes” outcome on that
predictor variable than for a subject with a “no” outcome on
that predictor variable. For example, for a subject with a prior
MI compared to a subject without a prior MI, the odds of
significant overall graft worsening are 1.47 times larger, with a
95% CI of (1.17, 1.85).
The ORs for the continuous variables indicate how much
greater the odds of significant graft worsening increase for a
subject with a 1-unit increase in the predictor variable. For
example, for a 10 mm Hg increase in mean arterial pressure,
the odds of significant graft worsening are increased by
exp(10*0.0126) 5 1.13 times, with a 95% CI of (1.02, 1.26).
Table 4 shows the results of the GEE model with the
same predictor variables as in Table 3, except for the
angiographic variables, which were omitted. It is shown
because 98 additional subjects are included in the model.
Although the parameter estimates and estimated variances
are close to those in Table 3, it is clear that the inclusion of
the angiographic variables and the deletion of the 98
patients with some missing data does affect the other
parameter estimates. In particular, the intercept shows the
greatest change, followed by the dichotomous variable for
female.
DISCUSSION
This study defined the prognostic factors for risk of athero-
sclerotic progression in SVGs in the large and well-
characterized Post-CABG patient population. In addition,
the relative importance of the prognostic factors (in terms of
reduction in deviance) was ascertained. These factors (in
order of their reduction in deviance) were maximum percent
stenosis in the graft at baseline angiography; years since
SVG placement; moderate (per the Post-CABG protocol)
treatment of LDL cholesterol; a history of prior MI;
elevated triglyceride level; small minimum graft diameter;
low HDL and high LDL cholesterol levels; high mean
arterial pressure; low ejection fraction; male gender; and
current smoking. The model permits one to calculate the
probability of atherosclerosis progression in grafts in this
patient cohort and to assess quantitatively the relative
importance of each of the variables.
Comparison with prior studies. Campeau et al. (13)
reported that the treatment effect of aggressive compared
with moderate LDL-C lowering in the Post-CABG trial
did not differ significantly among subgroups of age (,60 or
.60 years), gender, or CHD risk factors such as smoking,
hypertension, diabetes mellitus, HDL ,35 mg/dl versus
$35 mg/dl, and tryglyceride levels ,200 mg/dl compared
to $200 mg/dl. They found that the change in minimum
lumen diameter was in the same direction for all subgroup
categories and there were no significant interactions with
treatment.
Here we found a significant association of graft age and
progression of atherosclerosis. True atherosclerosis, defined
by the World Health Organization as the presence of foam
cells (14), has never been observed before the first postop-
erative year and seldom before the fourth year (15,16).
Several studies involving two to four repeat angiographic
examinations have reported a progressive increase in late
obstructive changes with increasing time after the initial
operation. In one study of 98 grafts in 82 patients that
appeared normal one year after surgery, late obstructive
changes were observed in 24 grafts at five to seven years and
in 62 between 10 and 12 years (17). Cosgrove et al. (18)
studied 665 patients who underwent repeat coronary bypass
because of graft failure and/or progression of disease in the
native coronary arteries. They reported an incidence of
reoperation of 2.7% at 5 years, 11.4% at 10 years, and 17.3%
Table 4. Estimates of Parameters, Standard Errors, and Odds Ratios for GEE Model for Graft Worsening as a Function of Baseline
Variables (no angiographic variables)
Parameter Odds Ratio
Estimate SE p Value Estimate 95% CI
Intercept 23.5800 0.7169 , 0.0001
Years since CABG operation 0.1924 0.0200 , 0.0001 1.21 (1.17, 1.26)
LDL-C lowering treatment (aggressive) 20.5488 0.1024 , 0.0001 0.58 (0.47, 0.71)
Prior MI* 0.3165 0.1080 0.0034 1.37 (1.11, 1.70)
Triglycerides (mg/dl) 0.0021 0.0008 0.0073 1.00** (1.00, 1.00)**
HDL cholesterol (mg/dl) 20.0216 0.0061 0.0004 0.98 (0.97, 0.99)
LDL cholesterol (mg/dl) 0.0111 0.0026 , 0.0001 1.01 (1.01, 1.02)
Mean arterial pressure (mm Hg) 0.0137 0.0050 0.0065 1.01 (1.00, 1.02)
Ejection fraction 20.0106 0.0045 0.0197 0.99 (0.98, 1.00)
Women* 20.7036 0.2582 0.0064 0.49 (0.30, 0.82)
Current smoker* 0.3673 0.1627 0.0240 1.44 (1.05, 1.99)
*1 5 yes, 0 5 no. **Accurate to three decimal places.
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at 12 years following initial grafting. Solymoss et al. (19)
studied 119 consecutive patients who had symptom-
directed angiography 17 to 203 (mean 95 6 5) months after
coronary bypass. They observed late graft changes compat-
ible with atherosclerosis or thrombosis in 70% of patients. A
stepwise logistic regression analysis identified graft age as an
independent risk factor for angiographic progression.
Consistent with the results of the Post-CABG study (8),
substantial data are present in the literature to support a role
for elevated lipid levels in the progression of SVG athero-
sclerosis. Campeau et al. (3) observed that elevated plasma
cholesterol and LDL as well as low HDL were associated
with atherosclerotic progression in grafts. Daida et al. (20)
found a strong relationship of cholesterol level and vein graft
obstruction in 284 patients a mean of seven years after
bypass. Stenosis $70% was present in 12% of grafts in
patients with serum cholesterol ,200 mg/dl, 39% in pa-
tients with serum cholesterol 200 to 239 mg/dl and 43% in
patients with serum cholesterol $240 mg/dl. Additionally,
elevated serum lipid levels, including elevated triglyceride
levels, have been associated with late clinical events follow-
ing bypass surgery, including MI and need for further
revascularization, which may have resulted from graft failure
associated with atherosclerosis (21,22). Neitzel et al. (23)
found atherosclerosis in 71% of the 50 grafts in patients who
had reoperation or died six to 12 years after their first bypass
operation. The prevalence of coronary artery disease risk
factors in this cohort was compared to a control population
of 535 survivors who did not require another revasculari-
zation procedure during the same period. Higher total
cholesterol and triglyceride levels (p , 0.001) and lower
high-density lipoprotein levels (p , 0.05) were found in the
serum of patients who required a second bypass operation
than in the controls. The stepwise logistic regression anal-
ysis of Solymoss et al. (20) identified apolipoprotein B and
Lp(a) levels as independent risk factors for progression.
A number of other studies have also identified Lp(a) as
predictive of SVG atherosclerosis (3,24,25). In an autopsy
study, Lie et al. (15) found atherosclerosis in 3 of 26 (11.5%)
grafts from normolipemic patients and in 11 of 14 (78.6%)
grafts from hyperlipemic patients who survived 13 to 75
months following surgery. Atkinson et al. (26) did an
autopsy study on 56 patients 12 to 168 months following
coronary bypass. Hypercholesterolemia was present in 68%
of patients in whom graft atherosclerosis was found but only
in 15% of patients having grafts with only intimal hyper-
plasia (p , 0.02).
In this study, we found that maximum graft stenosis and,
also, minimum graft diameter at baseline angiography were
predictive of angiographic progression between baseline and
follow-up angiography. Most, but not all, of the available
data are consistent with our findings. Campos et al. (27)
presented data on long-term follow-up of normal and
minimally diseased (,35% stenosis) SVGs. This group
studied 62 patients with a postoperative angiogram showing
normal or minimally diseased SVGs 6.1 6 2.1 years after
their initial bypass operation. A repeat angiogram was
performed 5.1 6 1.4 years later and this was used to assess
graft progression. More than half of these grafts remained
normal or minimally diseased. Data from Mehta et al. (28)
also suggest a favorable outcome if SVGs are normal at
baseline. Kouz et al. (29) in a study of 144 patients one year
and 8 6 5 years post-SVG placement reported a positive
correlation between early graft narrowing and late graft
occlusion.
In our study, higher mean arterial pressure was associated
with progression of SVG atherosclerosis. In the study of
Campos et al. (27), severe hypertension was identified as a
risk factor for atherosclerotic progression.
The study of Cosgrove et al. (18) found, as did the
present study, that left ventricular dysfunction also predicted
progression of vein graft atherosclerosis.
In Post-CABG, female gender was associated with re-
duced SVG atherosclerotic progression, although this was
one of the lesser risk factors. The investigators are aware of
no other data that speak to this issue.
Current smoking was significantly associated with SVG
atherosclerosis progression in Post-CABG patients, though
it appears to be one of the lesser risk factors from a
quantitative point of view. This is consistent with data from
studies that have shown angiographic progression of SVG
atherosclerosis in smokers compared to nonsmokers (30)
and graft thrombosis (31).
There was no effect of baseline therapy with antithrom-
botic agents in this study. In a randomized trial reported by
Chesebro et al. (32), the combination of dipyridamole and
aspirin was compared to placebo for the reduction of SVG
occlusion. At one month and one year a significant reduc-
tion occurred in graft occlusion as a result of treatment with
aspirin and dypyridamole. These two studies are not directly
comparable, however, because we had very few occlusions
and the Chesebro study was based entirely on occlusion.
Clinical implications. An understanding of the prognostic
factors that lead to the progression of SVG atherosclerosis
provides a rational strategy for designing therapeutic inter-
ventions. In addition to showing that more intensive lipid
lowering is important (this was also the main conclusion of
the Post-CABG trial), our data suggest that smoking
cessation should reduce atherosclerosis progression in
SVGs.
The main results of the Post-CABG trial (8) and those of
the Cholesterol-Lowering Atherosclerosis Study (CLAS I
and II) (33,34) indicate the importance of lipid lowering. In
addition, these data suggest the importance of blood pres-
sure control. Also, a reasonable hypothesis arising from this
study is that reduction of triglycerides may be effective in
preventing SVG atherosclerotic progression.
Study limitations. This study was a secondary analysis of
the Post-CABG clinical trial data. Because patients in this
study were accrued between 1989 and 1991, certain candi-
date prognostic factors, including fibrinogen and apoli-
poprotein A, were not studied in all patients. Further, the
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analysis presented herein should be considered to be explor-
atory because many analyses were undertaken to derive the
final model. The equation derived to calculate the proba-
bility of atherosclerosis progression is strictly applicable only
to the Post-CABG population and should be validated on
an independent data set. However, it seems likely that it
would apply qualitatively to other coronary populations with
similar baseline characteristics. The degree of baseline
atherosclerotic disease no doubt varied in this population,
which was studied one to 11 years following initial surgery,
and the grafts in these patients were likely at different points
in the development of their atherosclerotic disease. For this
reason, the time interval post-CABG was incorporated into
the multivariate analysis.
Conclusions. This study identified Post-CABG patient
and graft characteristics associated with SVG atherosclero-
sis progression including: maximum stenosis of the graft at
baseline angiography; years post-SVG placement; the mod-
erate LDL-C lowering strategy; prior MI; high triglyceride
level; minimum graft diameter; low HDL cholesterol; high
LDL cholesterol; high mean arterial pressure; low ejection
fraction; male gender; and current smoking. These data
provide a basis for rational risk factor management to
prevent progression of SVG atherosclerosis.
Reprint requests and correspondence: Dr. Michael Domanski,
National Heart, Lung, and Blood Institute, Bethesda, Maryland
20892.
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